HURA
TuHURA Biosciences, Inc. (HURA) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Extremely negative cash conversion cycle suggests very rapid inventory turnover or supplier financing, which can support liquidity efficiency versus peers in working-capital-intensive retail models.
Very low leverage, with debt-to-equity near 0.02x and net debt to EBITDA near 0.02x, leaves balance-sheet flexibility that is stronger than more levered peers.
The current ratio and quick ratio are identical at 0.18x, indicating a tightly managed short-term asset base that can reduce idle capital versus peers with bloated working capital.
Weaknesses
Return on invested capital is negative at -1.37%, showing capital is not yet generating economic returns and lagging profitable peers.
Current and quick ratios of 0.18x indicate weak near-term liquidity, leaving the company more exposed than peers with stronger working-capital buffers.
The same negative cash conversion cycle that aids efficiency also implies structural dependence on supplier terms, which can be less resilient than peers with positive internal funding.
Opportunities
If management converts the very low leverage into inventory, store, or digital investment, the balance sheet could support faster scaling than more indebted peers.
Improving working-capital discipline from an already extreme cash conversion cycle could release cash and narrow the gap with peers that still tie up capital.
Any sustained improvement in invested-capital returns would have outsized peer impact because the current negative ROIC leaves substantial room for relative re-rating.
Threats
Persistently negative ROIC threatens long-term competitiveness because peers with positive capital returns can reinvest more aggressively and compound faster.
Liquidity remains fragile at 0.18x current and quick ratios, so peers with stronger short-term coverage may better absorb demand shocks or supplier tightening.
If supplier terms normalize, the unusually negative cash conversion cycle could reverse quickly, removing a key working-capital advantage versus peers.
Overall Score
HURA’s peer positioning is constrained by negative capital returns and weak liquidity, and its low leverage only partially offsets these structural disadvantages.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on TuHURA Biosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
